Peptide Compositions Targeting β-Catenin for Treatment of Endometriosis

USPTO published a patent application for peptide compositions targeting β-catenin for endometriosis treatment. The application covers peptides that bind β-catenin, prevent nuclear translocation, and modulate the canonical Wnt pathway. CPC classifications indicate therapeutic peptides (C07K 7/08) for gynecological conditions (A61P 15/02).

Pharmaceutical companies developing endometriosis therapies and peptide-based therapeutics should review the published claims for potential licensing or design-around considerations. Medical device manufacturers developing peptide-delivery systems may also need to assess patent landscape implications. This publication does not grant patent rights; applicants must successfully prosecute the application through examination to obtain enforceable patent protection.